TXN vs ADI: side-by-side analysis
Cross-read of TXN (Texas Instruments Incorporated) versus ADI (Analog Devices Inc.): TXN looks meaningfully overvalued at $288 versus a fair-value midpoint of $153, while ADI appears in our peer table. Our current rating for TXN is Sell.
Where TXN and ADI sit on fair value
TXN's composite fair-value range is $99.8–$207 (midpoint $153), versus a current price of $288. ADI is one of TXN's closest sector neighbours and shows up directly in the peer table inside our full report. The cross-read is editorial: same archetype expectations, same discount-rate philosophy, different operating model.
Both names are evaluated under the same six-factor decision overlay (customer value, unit economics, TAM, moat durability, risk profile, valuation) so comparing them is apples-to-apples rather than headline-multiple-to-headline-multiple. The rating differential between TXN and ADI is driven by where each lands across those six axes, not by who looks "cheaper" on a single screen.
Where they actually differ
TXN is classified as a mature-dividend stock; the archetype dictates our deceleration curve, terminal multiple, and probability weights. ADI, depending on its own archetype, will have its own calibration — and that is precisely why simple peer multiples can mislead. A 31.3× forward P/E with a PEG of 3.48 is not the same on TXN as it is on ADI unless they share the same growth profile, capital intensity, and moat half-life.
TXN's moat assessment is 9/10, and the full moat section in the report covers the source (network effects, switching costs, intangibles, scale, etc.) plus the timeline of any threats. The cross-read against ADI should focus on which company's economic profit (ROIC minus WACC) is wider AND more durable — that is the variable that dominates long-run total return between two same-sector names.
Which one wins on each dimension
Valuation: TXN looks meaningfully overvalued versus our fair-value midpoint. The full report's peer table compares TXN and ADI directly on P/E, PEG, EV/EBITDA, ROE, and operating margin. Risk: the bear case for TXN is bound by the kill-scenarios list in Section 2; the equivalent for ADI would need its own report. We do not co-rate two companies on a single page.
Capital allocation and growth runway typically separate same-sector pairs more than the headline numbers suggest. The full report's capital-allocation paragraph and TAM analysis are the lenses we recommend before deciding whether TXN or ADI is the better expression of the same theme.
Bottom line — TXN or ADI?
Our rating for TXN is Sell with a 87/100 confidence score; the rating already accounts for the relative-value information embedded in the peer table that includes ADI. The cross-read is most useful when the two companies are real substitutes in a portfolio (same factor exposure, same end markets, same archetype) — otherwise the comparison is theatre.
For the full evidence on TXN, including the explicit peer multiples versus ADI and the rest of the comp set, see the canonical report at /stocks/txn/analysis. For ADI's standalone report, see /stocks/adi/analysis.
Frequently asked questions
TXN vs ADI: which is cheaper today?
TXN looks meaningfully overvalued at $288 versus a fair-value midpoint of $153 (range $99.8–$207). The peer table inside the full report compares TXN and ADI directly on P/E, PEG, EV/EBITDA, ROE, and operating margin.
Is TXN a better buy than ADI?
Our current rating for TXN is Sell; we do not co-rate ADI on this page — see ADI's own report. The cross-read is most useful for relative positioning, not for choosing one over the other in isolation.
What archetype is TXN?
Texas Instruments Incorporated is classified as a mature-dividend stock, which determines our deceleration curve, terminal multiple, and probability weights. ADI's own archetype is in its own report.
What is TXN's moat score versus ADI?
TXN's moat score is 9/10. The full moat section covers source, durability, and threat timeline; ADI's moat assessment is in its own standalone report.
Research for educational purposes. Not personalised investment advice. See the full TXN report for the canonical evidence.